Peripheral Blood CD34+ Cell Enumeration as a Predictor of Apheresis Yield: An Analysis of More Than 1,000 Collections

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 5, 2012, Pages 763-772

  Gambell, Peter ^a   Herbert, Kirsten ^a   Dickinson, Michael ^a   Stokes, Kerrie ^a   Bressel, Mathias ^a   Wall, Dominic ^a,b   Harrison, Simon ^a,b   Prince, H Miles ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CD34; Disease; HPC A collection; Mobilization; WCC; Weight

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APHERESIS; ARTICLE; BODY WEIGHT; CD34 SELECTION; CELL COUNT; CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CRYOPRESERVATION; FECES ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CELL DYSCRASIA; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SARCOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BLOOD COMPONENT REMOVAL; BODY WEIGHT; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; RETROSPECTIVE STUDIES;

EID: 84859879114     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.002     Document Type: Article

References (32)

1. To L.B., Haylock D.N., Simmons P.J., et al. The biology and clinical uses of blood stem cells. Blood 1997, 89:2233-2258.
2. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
3. Nieboer P., de Vries E.G., Mulder N.H., et al. Long-term haematological recovery following high-dose chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation in patients with solid tumours. Bone Marrow Transplant 2001, 27:959-966.
4. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
5. Villanueva M.L., Vose J.M. The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma. Clin Adv Hematol Oncol 2006, 4:521-530.
6. Ljungman P., Bregni M., Brune M., et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010, 45:219-234.
7. Beyer J., Schwella N., Zingsem J., et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995, 13:1328-1335.
8. Juttner C.A., To L.B., Haylock D.N., et al. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high-dose melphalan or supralethal chemoradiotherapy. Br J Haematol 1985, 61:739-745.
9. Prince H.M., Page S.R., Keating A., et al. Microbial contamination of harvested bone marrow and peripheral blood. Bone Marrow Transplant 1995, 15:87-91.
10. Fruehauf S., Seggewiss R. It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement. Br J Haematol 2003, 122:360-375.
11. Mishra V., Vaaler S., Brinch L. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma. Clin Lab Haem 2003, 25:179-184.
12. Sutherland D.R., Stewart A.K., Keating A. CD34 antigen: molecular features and potential clinical applications. Stem Cell 1993, 11(suppl 3):50-57.
13. + hematopoietic stem and progenitor cells. Curr Prot Cytoms 1999, 6:6.4.1-6.4.22.
14. Bender J.G., To L.B., Williams S., et al. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992, 1:329-341.
15. Siena S., Schiavo R., Pedrazzoli P., et al. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000, 18:1360-1377.
16. Elliot C., Samson D.M., Armitage S., et al. When to harvest peripheral blood stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. J Clin Oncol 1996, 14:970-973.
17. + cells predicts the number of hematopoietic stem cells that can be collected by apheresis. Bone Marrow Transplant 1996, 17:509-515.
18. + cells after stem cell mobilization predict stem cell yield and post-transplant recovery. J Hematother 1997, 6:13-19.
19. Knudsen L.M., Gaarsdal E., Jensen L., et al. Improved priming for mobilization of and optimal timing for, harvest of peripheral blood stem cells. J Hematother 1996, 5:399-406.
20. + mononuclear cell counts as predictors of progenitor cell yield. Transplantation 1997, 37:79-85.
21. + cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 1998, 38:385-391.
22. + cell count reliably predicts autograft yield. Bone Marrow Transplant 1998, 22:125-130.
23. + cell count in the peripheral blood for timing apheresis and maximizing yield. Transfusion 1999, 39:442-450.
24. + cell enumeration. Cytotherapy 2004, 6:50-61.
25. Ford C.D., Pace N., Lehman C. Factors affecting the efficiency of collection of CD34-positive peripheral blood cells by a blood cell separator. Transfusion 1998, 38:1046-1050.
26. + cell determination by flow cytometry. J Hematother 1996, 5:213-226.
27. + cell counts based on the ISHAGE guidelines. Cytometry 1998, 34:61-70.
28. Sutherland D.R., Nayyar R., Acton E., et al. Comparison of two single-platform ISHAGE-based CD34 enumeration protocols on BD FACSCalibur and FACSCanto flow cytometers. Cytotherapy 2009, 11:595-605.
29. + hematopoietic stem and progenitor cells. Curr Prot Cytom 2003, 6:6.4.1-6.4.23.
30. Bensinger W., Appelbaum F., Rowley S., et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995, 13:2547-2555.
31. Maclean P., Parker A., McQuaker I., et al. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is underestimated in myeloma patients, possibly due to disease-related height loss. Bone Marrow Transplant 2007, 40:665-669.
32. + cell doses for autologous hematopoietic stem cell transplantation?. Bone Marrow Transplant 2003, 31:861-864.